Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rani Therapeutics Holdings Inc RANI

Healthcare Biotechnology
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The... see more

Recent & Breaking News (NDAQ:RANI)

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

GlobeNewswire 3 days ago

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

GlobeNewswire 11 days ago

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

GlobeNewswire October 23, 2025

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

GlobeNewswire October 23, 2025

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

GlobeNewswire October 17, 2025

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

GlobeNewswire October 17, 2025

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

GlobeNewswire August 7, 2025

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

GlobeNewswire July 15, 2025

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery 

GlobeNewswire July 14, 2025

Rani Therapeutics Announces Research Agreement with Chugai

GlobeNewswire May 19, 2025

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

GlobeNewswire May 13, 2025

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

GlobeNewswire March 31, 2025

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

GlobeNewswire March 26, 2025

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire March 25, 2025

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

GlobeNewswire February 5, 2025

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update

GlobeNewswire November 14, 2024

Rani Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 7, 2024

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

GlobeNewswire October 17, 2024

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

GlobeNewswire October 15, 2024

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire October 8, 2024